VBI Vaccines Inc/BC: directors' dealings · United States · SEC (Form 4)

About VBI Vaccines Inc/BC

VBI Vaccines Inc/BC (ticker: VBIV) is a United States-linked biopharmaceutical company listed on the NASDAQ. For international equity investors, it represents a small-cap, high-risk vaccine and immunology platform story rather than a broad-based commercial pharma franchise. The company traces its roots to Variation Biotechnologies (VBI) and its current structure was formed through a series of mergers completed between 2014 and 2016. Its corporate headquarters are in Cambridge, Massachusetts, United States, placing it in one of the world’s most important biotech clusters, while research and development activities are maintained in Ottawa, Canada, and GMP manufacturing capabilities are located in Rehovot, Israel. ([vbivaccines.com](https://www.vbivaccines.com/contact/?utm_source=openai)) VBI’s business model is built around proprietary vaccine science, primarily its enveloped virus-like particle, or eVLP, platform. The company has developed candidates designed to mimic the natural presentation of viruses and trigger strong immune responses. Its best-known asset has been its three-antigen hepatitis B vaccine, marketed under names including Sci-B-Vac, PreHevbrio, and PreHevbri depending on the market and partner structure. Beyond hepatitis B, VBI has pursued a broader pipeline that has included therapeutic hepatitis B programs, cytomegalovirus candidates, oncology immunotherapy programs, and coronavirus vaccine candidates. ([vbivaccines.com](https://www.vbivaccines.com/press-releases/oct-2017-offering-closing/?utm_source=openai)) From a competitive standpoint, VBI occupies a niche position in the global vaccine landscape. It does not compete with large-cap vaccine manufacturers on scale, but rather on differentiation of its delivery platform and antigen presentation approach. That makes the investment case highly binary: clinical data, regulatory decisions, and commercialization partnerships matter more than traditional volume-driven market share metrics. The company has also relied on partnerships to extend reach, including collaborations that supported commercialization in the United States, Europe, Canada, and parts of Asia-Pacific. This suggests a strategy focused on value realization through licensing and partnering rather than a fully integrated global sales model. ([vbivaccines.com](https://www.vbivaccines.com/press-releases/syneos-health-commercialization-partner/?utm_source=openai)) Geographically, VBI has a notably international operating footprint for a company of its size. The Cambridge headquarters supports corporate leadership, business development, commercialization, communications, and investor relations. Ottawa hosts discovery and preclinical work, while the Rehovot facility handles manufacturing and release activities. That footprint supports development and supply-chain flexibility, but also adds execution complexity and dependence on cross-border operations. Recent company disclosures have highlighted revenue contributions from product sales and partnership arrangements in 2023, while more recent communications also referenced a voluntary nationwide recall of PreHevbrio in the context of discontinuing company operations. For investors, VBIV remains an NASDAQ-listed, science-driven special situation where the valuation thesis hinges on intellectual property, partnering optionality, and the status of legacy vaccine assets. ([vbivaccines.com](https://www.vbivaccines.com/?utm_source=openai))